Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

The mechanisms underlying the resistance to immune checkpoint inhibitors (ICIs) therapy in metastatic urothelial carcinoma (mUC) patients are not clear. It is of great significance to discern mUC patients who could benefit from ICI therapy in clinical practice. In this study, we performed machine le...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Siteng, Zhang, Ning, Wang, Tao, Zhang, Encheng, Wang, Xiang, Zheng, Junhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477044/
https://www.ncbi.nlm.nih.gov/pubmed/32983112
http://dx.doi.org/10.3389/fimmu.2020.01900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477044/
https://www.ncbi.nlm.nih.gov/pubmed/32983112
http://dx.doi.org/10.3389/fimmu.2020.01900

Ejemplares similares